Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Horizant (Gabapentin Enacarbil) on Augmentation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients with diagnosis of RLS for more than one year.~2. Patients who are on DA therapy for 6 months or longer.~3. Patients who developed Augmentation (on stable dose of DA) lasting for 3 months or longer.~4. Augmentation severity rating scale of 5 to 15.~5. Both males and females~6. Age range = 18-85 year~Exclusion Criteria:~* Known Hypersensitivity to Horizant or Gabapentin products~* Peripheral neuropathy~* Radiculopathy~* Peripheral vascular disease~* Uremia \[abnormal blood urea nitrogen (BUN) or Creatinine on Comprehensive Metabolic Panel (CMP)\]~* Anemia~* Patients who are currently pregnant~* Patients who currently take opioids, lithium, anti-nausea medications (e.g. metoclopramide), dopaminergic antagonists (e.g. Haloperidol), 1st generation antihistamines (e.g. diphenhydramine, pseudoephedrine), anti-psychotic medications and iron therapy.~* Subjects with impaired decision making capability.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- open-label (Type: OTHER): open-label single arm study~Horizant, 600 mg oral once daily at 5 pm for 360 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).